quate oxygen uptake, oxygen transport, and oxygen delivery. In diseases with perfusion disorders; for example, chronic occlusive arterial disease, the oxygen uptake by the lungs is not altered and thus the oxygen saturation of arterial blood is normal. Such conditions may be present in the majority of cancer patients. Multiple processes including vascular abnormalities, intratumoral pressure gradients, and severe anemia may be involved in generating a hypoxic microenvironment in the tumor tissue. However, the meaning of these various mechanisms in vivo is not well understood.
The diagnosis of cancer is often accompanied by alterations in blood rheology that may have profound effects on microcirculatory flow in tumor tissue. The most frequent constellation at this time is a moderately to markedly increase in plasma viscosity (PV), red blood cell (RBC) aggregation and rigidity, and fibrinogen/fibrin turnover while hematocrit is low (reviewed in reference 5). Because of serious morphological deficiencies of newly formed intratumoral vessels, blood flow and thus perfusion and oxygenation of tumor tissue may be particularly sensitive to even minor changes in blood rheology. At the time of diagnosis of uterine cancer, mean PV and RBC aggregation is markedly higher as compared to that in patients with benign uterine diseases and healthy women (6, 7) . These rheological abnormalities must be interpreted as an immediate consequence of the overall tumor burden. Rheological variables return to the range of initial preoperative values within days to a few weeks after surgery for non-malignant disease (8) . In contrast to this, upon removal of the tumor masses a statistically significant drop of high PV and RBC aggregation toward normalization of rheological variables is demonstrable after standard surgery for primary ovarian cancer. According to serial testing, mean PV and RBC aggregation remain stable during subsequent adjuvant chemotherapy, but approached preoperative values 3 months after termination of chemotherapy (9) .
There are at least two good reasons to investigate and monitor rheological properties during cancer treatment because they might provide a link to the high risk of DVT during chemotherapy or radiotherapy and may also provide evidence of susceptibility of the target to systemic cancer therapy and thus prognosis of patients.
PATIENTS AND METHODS

Patients with Uterine Cancer
Most participants of this study represent a subpopulation of consecutive patients of a previous trial with suspected gynecologic malignancy, who underwent primary cancer surgery in the Department of Gynaecology/Oncology, City Hospital of Ruesselsheim (7) . The time range for inclusion of the first and last patients was 89 months and started in September 1992. Before the beginning of surgery, patients gave their written informed consent to the study. Patients were excluded if they had clinically significant renal, hepatic, or cardiac diseases; a history of cancer; or distant metastasis at the time of primary cancer diagnosis. A medical history was taken and a physical examination was performed with particular emphasis on possible thromboembolic risk factors including: age, menopausal status, BMI (body mass index), blood pressure, venous varicosities, preoperative immobility, and smoking. Preexisting diseases such as cardiovascular, renal, hepato-pancreatic, and liver disease and medication use was documented in a study protocol. None of the patients had received blood transfusions within 14 days before surgery. Routine preoperative testing included blood analysis, electrocardiography, chest radiography, ultrasound of the breast and pelvic organs, and impedance plethysmography. Before surgery patients underwent cystoscopy and proctoscopy and some patients with unknown abdominal expansion of tumor mass underwent intravenous pyelography, coloscopy, or computer tomography.
Surgery and Radiotherapy
All patients had a histologic diagnosis made during surgery. Surgery for endometrial cancer was performed by midline abdominal incision and included initial peritoneal lavage for cytologic evaluation, hysterectomy, bilateral salpingo-oophorectomy, omentectomy, appendectomy, and pelvic lymphadenectomy. Cervical cancer patients underwent surgery according to Wertheim Meigs. Three to 4 weeks postoperatively, all patients included in this study received four fractions of IR 192 HDR each week after loading radiation of the vaginal vault for one or more of the following indications:
• Patients with endometrial carcinoma of FIGO stage Ic and higher.
• Patients with endometrial carcinoma in whom removal of the vaginal vault was not performed.
• Patients with endometrial carcinoma with a tumor of poor histology grade (> II).
• Patients with cervical cancer with a FIGO stage Ia2 and higher (depth of invasion > 3mm and/or lymph-vascular space invasion).
Treatment dosage for microscopic or occult tumor was 4000 to 5000 cGy (centigray) and was in excess of 6000 cGy for clinically obvious tumor residuals. Vaginal irradiation therapy was followed by external pelvic irradiation in patients with more than five positive inguinal lymph nodes or unfavourable proliferation marker (Sphase > 10%). Preoperatively, extended-field radiation was performed in patients with cervical carcinoma of stage IIb and higher and in patients with endometrial carcinoma if positive pelvic lymph nodes or para-aortic nodal metastases were present.
Controls
Consecutive patients who underwent surgery for non-malignant uterine disease within a period of 3 months were asked to serve as a control group. All patients were scheduled for hysterectomy due to bleeding disorders, myoma, descent uterus, or dysmenorrhea. Apart from the indication for hysterectomy patients were healthy and Karnofski performance index was ≥ 90. None of them had a history of malignant disease or previous DVT. All gave their written informed consent and blood sampling took place the day before surgery.
Thrombosis Screening and Prophylaxis
Thrombosis screening was performed the day before surgery as well as on day 1, 3, 5, 7, 10 o.v. postoperatively, before each session of brachytherapy and at the first follow-up visit in about 6 months after cancer diagnosis. Impedance plethysmography (IPG) was used for none invasive DVT screening. Patients early recruited to the study received unfractionated heparin (3 * 5000 IE/d) for perioperative and postoperative DVT prophylaxis until 7 to 10 days after surgery. Prophylaxis regimen was changed to LMWH (1 * 3000 anti-Xa Certoparin o.v.) from up to the middle of 1994. When DVT was suspected on the basis of physical examination, patients' history, or a pathologic result of IPG, ascending venography of both legs was performed. A constant intraluminal-filling defect in deep veins was diagnosed as DVT. Patients with the clinical symptoms of pulmonary embolism (PE) were evaluated by ventilation-perfusion lung scanning. According to the recommendations at this time (10) patients with objectively prove of DVT received intravenous unfractionated heparin infusion (therapeutic range of activated partial thromboplastin time between 60 to 85 seconds) for 7 to 10 days. Intravenous heparin therapy was then shifted to a fixed dose of subcutaneous low molecular weight heparin therapy (Certoparin, NOVARTIS once 3000 anti-Xa units/day) and continued until the last session of radiotherapy.
Blood Sampling
Blood rheology investigations took place the day before surgery, before each of four sessions of brachytherapy and during aftercare 6 months postoperatively. To avoid diurnal variations blood sampling always took place between 8 and 10 A.M. After minimal stasis of the upper arm, blood was drawn from the antecubital vein using a 20-gauge needle supplied with a vacuum tube. For rheological estimations blood was collected in vacuum tubes containing 1:10 potassium ethylene diamine tetraacetic acid (EDTA) and sodium citrate 0.1 M/L (1:10; pH 4.5) for the determination of plasma fibrinogen concentrations. All rheologic tests were immediately performed in the laboratory of the department of gynaecology and obstetrics according to the guidelines of the International Committee for Standardization in Haematology (ICSH) (11) .
Laboratory Methods
Hematocrit (packed cell volume) was measured by micro centrifugation (normal range females: 37.0%-48.0%). Leukocyte (normal range: 3800-10,500/µL) and platelet concentrations (normal range: 140,000-345,000/µL) were obtained with a Coulter counter. RBC aggregation was estimated using a photometric rheoaggregometer developed by Schmid-Schönbein and colleagues (12) (MA1-Aggregometer; Myrenne, Roetgen, Germany). Blood samples (20 µL) adjusted to a standard hematocrit of 45% were placed between a transparent cone-plate system and rotated for 10 seconds at high shear rate of 600/sec to disperse all preexisting cell aggregates. Subsequently, the standardized extend of RBC aggregation during 10 seconds was determined by quantifying the increase in light transmission (measured by photodiodes) in two modes-during stasis-and while samples are subjected to low shear rate of 3/sec.
Light transmission increased at a rate proportional to the rate of RBC aggregation. The data were then processed by an integrated computer and expressed in arbitrary units. A normal reference range only exists for RBC aggregation during stasis (8-21) (13) . For determination of plasma viscosity and fibrinogen concentrations vacuum tubes were centrifuged for 20 minutes (2000g at 4°C) and a middle-layer of the plasma was obtained. Fibrinogen was measured according to the Clauss method (14) (normal range, 150-350 mg/dL). Plasma viscosity was determined using a capillary tube viscometer (KSPV 1 Fresenius, Bad Homburg Germany) at 37°C according to Jung and colleagues (25) and expressed in mPa s (normal range: 1.14-1.34 mPa s) (15) .
STATISTICS
Statistical analyses were conducted in collaboration with the Institute for Medical Statistics and Documentation of the University of Mainz using the SAS program system (SAS Institute, Berkeley, CA). The results were expressed as mean values ± standard deviations. Differences between groups or estimation time points were assessed with the Wilcoxon test for unpaired and paired samples and tested against zero. Correlation coefficients according to Spearman were calculated. Significance was assigned as p < 0.05.
RESULTS
A total of 38 patients with uterine cancer participated in the study, including 12 women with cervical cancer and 26 with endometrial cancer. All underwent surgery and subsequent brachytherapy of the vaginal vault, which was commenced 21 days postoperatively (range, 16-31 days). Controls consisted of 44 otherwise healthy women with benign uterine diseases. Baseline characteristics of patients and controls and tumor prognostic variables are summarized in Table 1 . Among controls and patients with cervical cancer, Mean age and the number of premenopausal women was statistically significant- In four patients with cervical cancer blood transfusion were repeated within 10 days postoperatively. During radiotherapy, no additional substitutions were needed. All patients were available after termination of pri-mary therapy and final blood sampling took place between 5 and 6 months postoperatively (6 months control).
LABORATORY RESULTS
Before Surgery and Before HDR-AL Preoperatively in patients with endometrial cancer PV and RBC aggregation (stasis and low shear) and initial PV in cervical cancer patients were significantly higher as compared to those of patients with non-malignant uterine tumors ( Table 2) . After surgery and before the first session of HDR-AL, means for all three parameters had dropped into the preoperative range of values of the controls. Blood transfusions due to significant blood loss during surgery were needed in more than 80% of cervical cancer patients who had an increased hematocrit postoperatively. Initial plasma fibrinogen levels were significantly higher in cancer patients compared to the controls and remained high before the beginning of radiotherapy. In cervical cancer patients, beforesurgery mean platelet count was significantly higher as compared to the control-values. Preoperatively, PV was significantly correlated with fibrinogen levels in patients with endometrial cancer but not in cervical cancer patients. RBC aggregability was significantly correlated with fibrinogen levels in cervical cancer but not in patients with endometrial cancer (Table 3) .
During HDR-AL and After the End of Primary Therapy Plasma viscosity continuously declined in the course of HDR-AL for treatment of endometrial cancer. Before the third session, patients of both cancer types presented lowest PV that regained thereafter and exceeded preoperative values 6 months postoperatively. Throughout HDR-AL, mean PV remained above the control values. However, these changes compared to the initial values were not statistically significant in both groups (Fig. 1) . While serial estimations of RBC agg. (stasis) revealed only minor changes during radiotherapy, low shear RBC aggregation decreased until the end of HDR-AL within a range of 25 and 30. Six months postoperatively, values were lowest in patients with endometrial cancer but had exceeded the initial preoperative results in cervical cancer. These changes were not statistically significant compared to the pre-treatment results (Fig. 2) . Hematocrit continuously and significantly increased during HDR-AL in endometrial cancer patients but was significantly decreased before the third session in cervical cancer patients and remained low 6 months postoperatively ( Fig. 3 ). RBC aggregation (stasis), blood cell counts, and fibrinogen levels during HDR-AL are shown in Table 4 . Mean fibrinogen levels moderately decreased in both treatment groups throughout HDR-AL but upon termination of treatment 6 months postoperatively climbed to the levels of the values before commencement of HDR-AL. Platelet and leukocyte counts significantly decreased until the last session of irradiation in endometrial cancer patients and remained low 6 months postoperatively.
DISCUSSION
The influence of modern radiotherapy on rheological properties in uterine cancer patients using HDR afterloading technique has not yet been investigated and although the current results are based on a rather small number of patients, there are some interesting aspects generated by this study.
During intrauterine/vaginal radium application for 12 to 24 hours in uterine cancer patients, an incidence of DVT between 2.5% and 6.8% has been reported, irrespective of whether thrombosis prophylaxis with either a daily dose of subcutaneous low-molecular-weight heparin or oral anticoagulation with warfarin was given (16) (17) (18) . Beside shorter exposition times to radiation and lower costs, HDR-AL offers practical advantages for the patient, because treatment can be done on an outpatient basis. Unlike the high incidence of DVD during former radium therapy, HDR-AL irradiation in this trial was not associated with either symptomatic thrombosis nor was thrombosis suspected by noninvasive screening methods. In accordance with previous results (6) , untreated patients with uterine cancer provide a hematocrit-independent hyperviscosity, which is caused by higher PV and RBC aggregation, and high fibrinogen levels while the hematocrit is in the normal range when compared with otherwise healthy women with nonmalignant uterine disease. Upon surgery, rheo-logic variables tended to be lower in endometrial cancer patients. Compared to the starting point before surgery, the maximal mean reduction of RBC aggregation, PV, and hematocrit during HDR-AL was approximately 7%, 11%, and 12%, respectively. Thus the misbalance of plasmatic and cellular compounds of blood viscosity remains stable throughout treatment. The temporary increase in PV until the beginning of the second HDR-AL session in cervical cancer patients may be explained by the necessity of more extensive surgery in the well-vascularized parametral pelvic area with particular and prolonged coagulation activation as a consequence. In patients undergoing surgery for non-malignant conditions; i.e., total hip or knee arthroplasty, PV was decreased on the first postoperative day and thereafter increased above the preoperative values on the seventh and fourteenth day, respectively. Six to eight weeks after surgery, PV had returned to preoperative levels (8) . The cause of the continuous decrease in PV during irradiation with lowest values before the third session in cervical and endometrial cancer patients approximately 6 weeks after surgery is as speculative as is the origin for the increase in blood viscosity in patients with solid tumors.
Abnormally high coagulation turnover in patients with solid malignant tumors is believed to be the most common reason for high blood viscosity and most likely the background of higher PV and RBC aggregation in the cervical cancer patients according to the correlation analysis of hemorheologic variables and plasmatic fibrinogen in this and other trials (7, 19, 20) . A host of unspecific tumor-associated actions increase blood viscosity in cancer, e.g., the host's immune response to the tumor, inflammatory processes, and the commonly older age of patients that is physiologically accompanied by hypercoagulability. Besides tumor-induced vascular damage, many solid tumors are found to have specific coagulation activating/fibrinolysis inhibiting pathways through the presence of transmembrane tissue factor (21), tumor procoagulants (22) , plasminogen activator inhibitor (23), or activated protease activated receptor 1-4 (24, 25) . Basically, microvascularity of solid tumors is a chronic focus of coagulation activation due to its chaotic vascular network that is characterized by a lack of smooth muscle cells, nervous regulation, and incomplete or even absent endothelial lining. Finally next to reduced oxygen supply, tumor growth itself leads to tissue hypoxia and the latter, in turn, is a strong stimulus for expression of genes encoding factors that promote coagulation activation (26) . However, coagulation activation alone may not account for higher PV in cancer patients. While fibrinogen levels postoperatively increased and remained higher during the postoperative period and during HDR-AL, hemorheologic variables showed a contrary course. Thus removal or reduction of the tumor mass contemporary reduced the extent of the increased hemorheologic variables. A temporary reduction in PV during cancer treatment followed by an increase after termination of therapy has previously been found in patients receiving chemotherapy for breast (27) and ovarian cancer (9) and in some cancer types the extent of rheological changes has been shown to correlate with the prognosis and progression of disease (6, 20, 28, 29) .
The clinical importance of lower PV during the initial phase of radiotherapy and the subsequent increase toward the end of treatment is hypothesis-generating and cannot be interpreted by the methods of the current trial. However, the course of rheologic results may be influenced by the effect of irradiation on tumor substance. Such hypothesis cannot be proven directly and correlation of rheologic variables during radiotherapy with the outcome of patients will be the only practical approach in this respect. 
